Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010191 · ClinicalTrials.gov registry record · NA
Harnessing Placebo Effects: Non-Deceptive Use of Placebo in Irritable Bowel Syndrome (IBS)
A NA study of Irritable Bowel Syndrome, sponsored by Harvard University Faculty of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01010191 is a NA study of Irritable Bowel Syndrome that has completed, run by Harvard University Faculty of Medicine. The registered enrollment target is 70 participants, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01010191, a NA study of Irritable Bowel Syndrome, has completed, sponsored by Harvard University Faculty of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Irritable bowel syndrome patients will be given either placebo pill or no treatment for a period of 3 weeks.
Conditions Studied
Interventions
- OTHER Sugar pill
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01010191
The ClinicalTrials.gov registry entry for NCT01010191 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (51% lower). The listed sponsor is Harvard University Faculty of Medicine, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Sugar pill is the first listed.
NCT01010191 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01010191 about?
NCT01010191 is a clinical study titled "Harnessing Placebo Effects: Non-Deceptive Use of Placebo in Irritable Bowel Syndrome (IBS)". Irritable bowel syndrome patients will be given either placebo pill or no treatment for a period of 3 weeks.
What is the current status of trial NCT01010191?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2008-07. Estimated completion is 2010-04.
What conditions does trial NCT01010191 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
What interventions are being tested in trial NCT01010191?
The interventions under investigation include: Sugar pill (OTHER).
Who is sponsoring clinical trial NCT01010191?
This trial is sponsored by Harvard University Faculty of Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01010191 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
RECRUITING · NA
-
GI Alpha-Gal Study
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
-
IBS Skin Patch Test Food Allergy Study
RECRUITING · NA
-
Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome
RECRUITING · NA
-
Well-being in IBS: Strengths and Happiness (WISH) 2.0
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.